Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Therapy Combined With Radical Surgery for Stage II and IIIA SCLC
NCT03523234Unknown
- Start
- Oct 2018
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Randomised, open-label trial in small cell lung cancer (SCLC) (2 arms). Primary endpoint: 5-year overall survival rate. Status: unknown.
02
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03523234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523234.